ArticleFrontiers in neuroscience2026
Graphomotor performance as a quantitative marker of Alzheimer's disease: a tablet-based case-control ROC study.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: From the clinical and neurobiological perspective of cortico subcortical loop concepts, Alzheimer's disease (AD) is associated with progressive deterioration of cognitive, emotional, and motor functions, which can be assessed subclinically using digital motion tracking technology in an electromagnetic digitizing tablet technology. Graphomotor analysis provides a source of sensitive digital biomarkers with potential applications in the early diagnosis and monitoring of AD. Methods: A case-control study was conducted including 72 patients with clinically diagnosed Alzheimer's disease (AD) and 44 cognitively healthy controls. Participants performed three graphomotor tasks (signature, free drawing, and the Trail Making Test A/B) using a digitizing tablet. Temporal, kinematic, and pressure-related parameters were recorded, including execution time, path length, mean and maximum velocity, pressure variability on the surface, and total harmonic distortion indices. Temporal measures reflected the duration and timing structure of task execution, kinematic measures described movement speed and variability, and pressure-related measures quantified the force applied by the pen and its stability during graphomotor performance. Statistical analysis was performed using the Mann-Whitney Findings: Patients with Alzheimer's disease exhibited significantly longer execution times, reduced mean and maximum velocities, and greater variability of velocity and pressure compared with healthy controls. In the signature task, kinematic measures showed the strongest discriminatory power, whereas in the drawing task, pressure variability emerged as the most sensitive parameter. In the Trail Making Test A, patients with AD performed significantly worse than controls across temporal, kinematic, and pressure domains, and the majority were unable to complete part B. ROC analyses demonstrated that execution time in TMT A (AUC 0.79; 95% CI 0.71-0.86), maximum velocity in TMT B (0.77; 0.68-0.85), and pressure variability (0.78; 0.69-0.85) achieved the highest diagnostic discriminatory value. Interpretation: Digital analysis of biomechanical signals from graphomotor tasks indicates significantly reduced motor control and diminished visuospatial-executive functioning in individuals with Alzheimer's disease (AD) compared with healthy controls. Patients with AD demonstrated longer task execution times, decreased movement velocity, and greater variability of pressure relative to the control group. These findings suggest that tablet-derived graphomotor parameters may serve as candidate digital markers of motor and executive dysfunction in Alzheimer's disease. Further external validation and longitudinal studies are needed before their use as diagnostic biomarkers can be recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.